Clinical Trial

ALDH2 Single Nucleotide Polymorphisms and Prognosis of Esophageal Cancer Patients

Recruiting
View on ClinicalTrials.gov →
Summary
Alcohol consumption, smoking, and betel nut chewing have been proven to be closely associated with the risk of esophageal cancer (EC). Recent studies have shown that alcohol-related detoxification genes in the ALDH family influence individual susceptibility to esophageal cancer. Aldehyde dehydrogenase 2 (ALDH2) is one of the most important enzymes in the ALDH family, involved in the metabolism of alcohol, acetaldehyde, and environmental aldehydes in the human body. We hypothesize that functional variations in ALDH2 may have a significant impact on the survival of esophageal cancer patients. This study aims to investigate the correlation between ALDH2 gene polymorphism and the survival of esophageal cancer patients.
Trial Details
NCT Number NCT07322627
Lead Sponsor National Taiwan University Hospital
Conditions Esophageal Cancer
Enrollment 700 participants
Start Date 2025-12-08
Primary Completion 2027-10-31 (estimated)
Study Completion 2027-10-31 (estimated)
Updated on ClinicalTrials.gov 2026-01-07